If you enjoyed this episode, you can listen to all episodes from The BioInsights Podcast wherever you normally get your podcasts. Follow the Podcast to make sure you don't miss the next episode. Could both tell me a bit about your backgrounds, and the current work you do? EM: My story starts with a PhD in stem cell biology back in 2006, when induced pluripotent stem cells (iPSCs) were first discovered.
Writer/editor of words about science and feminism. Part of the @HexScience coven. Made in Scotland from girders.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Roisin McGuigan
Forget Astronomical, Try Genomical
Genomics could soon outpace other scientific disciplines as the king of big data, but there could be problems ahead… Roisin McGuigan | 08/25/2015 The genomics revolution is uncovering more insights into human biology than ever before, but some researchers foresee a problem on the horizon: just what will we do with all that information?
Reuse, Recycle, Regenerate
Two repurposed drugs prevent neurodegeneration in mice – and both are already in clinical use Roisin McGuigan | 05/10/2017 “As a neurologist, I was appalled by how little we could do to treat neurodegenerative diseases in humans, compared to our extraordinary advances in other branches of medicine,” recalls Giovanna Mallucci, a researcher with the UK Medical Research Council (MRC).
Viagra and Vision: the Long and the Short of it
Are a significant number of users risking retinal damage? Roisin McGuigan | 11/14/2014 In clinical trials of the erectile dysfunction drug Viagra, it has been observed that high doses can cause transient visual disturbances in otherwise healthy subjects, including blurred vision and photophobia.
Innovation Versus Exnovation
Sometimes, we need to go backwards to go forwards in medicine Roisin McGuigan | 12/06/2017 Innovation drives translational science forwards – but what happens after an innovation has been adopted?
Translating Science into Signs
One student’s mission to boost scientific sign language Roisin McGuigan | 08/23/2017 Liam Mcmulkin, a second year life sciences student at the University of Dundee, UK, was facing a translational problem; as a deaf student, the dearth of complex scientific terms available in British Sign Language (BSL) was making life difficult. “My interpreter has to fingerspell words. Can you imagine sitting in a class, with your lecturer unable to pronounce complex scientific terms?” asks Mcmulkin.
The Hunt for an HD Blood Test
Do we finally have an effective blood biomarker for studying the progression of Huntington’s disease? Roisin McGuigan | 07/05/2017 Huntington’s disease (HD) is a devastating neurodegenerative disorder with no cure or disease-modifying treatments. Caused by an expanded trinucleotide repeat of the DNA bases cytosine-adenine-guanine (CAG) in the Huntingtin gene, it is primarily an inherited disease. Symptoms commonly arise between the ages of 30 and 50, but can begin as early as infancy.
From Acne to MS
Multiple sclerosis (MS) is a demyelinating disease with no cure. Some therapies are available to alleviate symptoms, which range from the physical to the psychiatric, but adverse reactions and drug costs mean that improvements are needed. We spoke to one researcher who helped to uncover a new potential therapy for MS: minocycline, a broad-spectrum antibiotic that is commonly used to treat acne. Luanne Metz, first author of the associated paper (1), tells us more.
A Cup of Tea a Day...
For thousands of years, and in many different cultures around the world, hot tea has been considered a health-giving brew. The humble beverage has been linked to the treatment of many diseases, from cancer to cognitive decline – and now glaucoma, according to a recent study published in the British Journal of Ophthalmology (1). “Previous studies have suggested that caffeine consumption may be associated with glaucoma.
Pain and Vision Gain
An analgesic is helping researchers explore new drug targets for sight-threatening diseases Roisin McGuigan | 01/09/2018 Pentazocine is an opioid most commonly used to treat pain – but could it also be used to save sight? A team of researchers from Georgia, USA, previously found evidence that pentazocine can protect the cones of the retina – and have received a US$1.14 million grant from the National Eye Institute to explore the connection further.
All Eyes on Biopharma Trends
The Medicine Maker and Ireland’s National Institute for Bioprocessing Research and Training (NIBRT) have collaborated on numerous occasions – perhaps you recall our cover feature from 2016 (here). More recently, The Medicine Maker and NIBRT teamed up to learn more about current manufacturing practices and trends in the biopharma industry, and where the field is heading next, by conducting a survey of industry professionals. You can download the full survey report – for free – here (1). Our goal?
Eyecare Sans Frontières
Back in 1973, Orbis was founded by a visionary Texan ophthalmologist who wanted to combine eyecare and aviation By 1982, the Flying Eye Hospital was born, and was transporting volunteers worldwide to provide eyecare and outreach programs to those who needed it most Now, the Orbis Flying Eye Hospital is in its third-generation, and is expanding its global reach as well as its eyecare and training capabilities Join us on a visual tour of this state-of-art aircraft, and hear from some of the...
Bearfaced Research
A new method for discovering antibiotics makes use of an unusual source of complex microbial communities Roisin McGuigan | 11/22/2018 A team of scientists has developed a technology that rapidly assesses antibiotics using microbes from a curious source: saliva taken from the East Siberian brown bear.
Bearfaced Research
Fields & Applications Mass Spectrometry, Pharma & Biopharma A new way of discovering antibiotics makes use of an unusual source of complex microbial communities Roisin McGuigan | 11/07/2018 A team of scientists has developed a screening technology for antibiotics using microbes from a curious source: saliva taken from an East Siberian brown bear. Why would anyone want to collect bear drool?
Time for Pharma to Deliver?
For the vast majority of pharmaceutical products, data on safety for pregnant and lactating women and their fetuses and babies is not available. But going without essential medication is not the right solution – failing to treat health conditions could lead to equal or increased risk for mother and child. Here, we seek the path to a more enlightened approach.
Bearfaced Research
A new method for discovering antibiotics makes use of an unusual source of complex microbial communities Roisin McGuigan | 10/17/2018 A team of scientists has developed a technology that rapidly assesses antibiotics using microbes from a curious source: saliva taken from the East Siberian brown bear.
A Tall Task
Roisin McGuigan | 10/17/2018 The Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) was mandated in 2016 by the 21st Century Cures Act (1). PRGLAC was charged with providing advice and guidance to the Secretary of Health and Human Services (HHS) on activities related to identifying and addressing gaps in knowledge and research on safe and effective therapies for pregnant and lactating women.
The True Cost of Falsified Medicine
Around one in every eight essential medicines in lower income countries may be of low quality, or an outright fake. This was the conclusion of a review and met-analysis performed on relevant studies in five databases, including Pubmed and Embase, which allowed researchers to examine over 350 previous studies, which between them tested more than 4,000,000 drug samples.
Time for Pharma to Deliver?
For the vast majority of pharmaceutical products, data on safety for pregnant and lactating women and their fetuses and babies is not available. But going without essential medication is not the right solution – failing to treat health conditions could lead to equal or increased risk for mother and child. Here, we seek the path to a more enlightened approach.
Eliminating Side Effects In Silico
Next-generation pain medications developed with computer simulations could improve on current opioid offerings Roisin McGuigan | 10/17/2018 “My group has studied the biology and pharmacology of opioid receptors on peripheral sensory neurons for over 25 years”, says Christoph Stein, Director, Department of Anesthesiology and Surgical Intensive Care Medicine, Charité – Universitätsmedizin Berlin.
From Bench to Bedside and Back Again
Sitting Down With... James Wilson, Rose H. Weiss Professor and Director, Orphan Disease Center, Professor of Medicine and Pediatrics, University of Pennsylvania, USA Roisin McGuigan | 10/11/2018 As an undergraduate, I was interested in the physical sciences, and had planned on attending graduate school to do chemistry.
Bringing Alzheimer’s in from the Cold
Bringing Alzheimer’s in from the Cold With big pharma seemingly pulling out of the field, what hope remains for novel treatments for Alzheimer’s disease? Here, we gain insight from a small but pioneering company and researchers in the Alzheimer’s research space to discover that – with the support of the wider community – there are significant reasons to be hopeful. You’d be forgiven for thinking that the pharma industry has completely abandoned Alzheimer’s disease (AD) research.
Bringing Alzheimer’s in from the Cold
With big pharma seemingly pulling out of the field, what hope remains for novel treatments for Alzheimer’s disease? Here, we gain insight from a small but pioneering company and researchers in the Alzheimer’s research space to discover that – with the support of the wider community – there are significant reasons to be hopeful. Roisin McGuigan | 08/15/2018 You’d be forgiven for thinking that the pharma industry has completely abandoned Alzheimer’s disease (AD) research.
All Eyes on Biopharma Trends
All Eyes on Biopharma Trends What are the hot topics in biopharma manufacture? What are the challenges? And where do we need to go? We provide hard data, expert insight, and thoughts for the future in a three part series. Here, we present Part 1. By Roisin McGuigan and Stephanie Sutton July 2018 The Medicine Maker and Ireland’s National Institute for Bioprocessing Research and Training (NIBRT) have collaborated on numerous occasions – perhaps you recall our cover feature from 2016 (here).
The Winning Formula
In December 2017, we celebrated the 15 most exciting drug development and manufacturing technologies in The Medicine Maker’s annual Innovation Awards. But which were truly the most groundbreaking? We asked you, our readers, to decide – and we received an overwhelming response. Here, we introduce you to some of the personalities behind your top three picks – and follow their journey from initial inspiration to commercial innovation.
Medicina Ex Machina
Medicina Ex Machina The sci-fi inspired concern that artificial intelligence will one day rule the world is (mostly) unfounded, but it certainly could have a huge impact on drug discovery. By Roisin McGuigan May 2018 Traditionally, pharma companies have been skeptical about the promise of artificial intelligence (AI).
Staying on Target
What characteristics make a cancer therapy more likely to effectively treat disease? Roisin McGuigan | 05/09/2018 Targeted therapies have had a huge impact on cancer treatment, in some cases significantly improving patient survival – but not in all cases. To treat the cancer, the drug must, of course, reach the tumor tissue and be taken up by cells, but this doesn’t always happen effectively despite targeting efforts. Why not?
Open Your Mind
Is the pharmaceutical industry overly reluctant to accept new ideas? Roisin McGuigan | 05/09/2018 It is universally acknowledged that the pharmaceutical industry can be conservative and slow to embrace change. With the health and safety of patients at stake if something should go wrong, this is hardly surprising. But does pharma’s skepticism run too deep?
Wake Up and Smell the Polymer
Caffeine isn’t just a catalyst to get you moving in the morning – it can also help create polymers for drug delivery Roisin McGuigan | 05/09/2018 Biocompatible gels have a range of applications in the pharma industry, including drug delivery.
Print it, Eat it
Could drug-containing QR codes fight fakes and avoid medication errors? Roisin McGuigan | 05/09/2018 With the rise of the smartphone, we have all become familiar with the QR code – used for everything from boarding an aircraft to paying for a service. But what if you could eat one and receive a dose of medicine? A team from the University of Copenhagen have taken the QR code a step further, creating a system to print QR codes on to an edible material as a means to create personalized medicines.
Medicina Ex Machina
Traditionally, pharma companies have been skeptical about the promise of artificial intelligence (AI). But with its potential to bring powerful new tools to the often slow and expensive drug discovery process – and its ability to predict which drugs are most likely to successfully run the clinical trial gauntlet, pharma companies are waking up to the fact that it really could be the future.
Stranger Than Fiction
Physicians are familiar with encountering patients who are unwell – which is in no way surprising. Many will have also treated (and potentially counseled) patients who are overly anxious about a minor issue – or prone to exaggeration. But only occasionally do ‘patients’ present themselves with a complaint that, upon further inspection, exhibits entirely fabricated – or even self-induced – symptoms.
A Problem Shared…
The ways in which individuals, organizations and companies can find solutions on the Internet is constantly expanding – from naming a new polar research vessel using an online vote (the Royal Research Ship Sir David Attenborough, if you’re interested) to funding innovative projects in art, science and technology through crowdfunding platforms like Kickstarter. But how can the crowdsourcing revolution benefit pharma?
Pain and Vision Gain
An analgesic is helping researchers explore new drug targets for sight-threatening diseases Roisin McGuigan | 12/19/2017 Pentazocine is an opioid most commonly used to treat pain – but could it also be used to save sight? A team of researchers from Georgia, USA, previously found evidence that pentazocine can protect the cones of the retina – and have received a US$1.14 million grant from the National Eye Institute to explore the connection further.
Eyecare Sans Frontières – Part Deux - The Ophthalmologist
In last month’s issue, we took a tour of Orbis’ new Flying Eye Hospital, and learned about the history of the organization. This month, we feature the stories of just a few of the dedicated volunteers who devote their lives to preventing and treating avoidable blindness and visual impairment across the world. Meet Rob Walters, volunteer surgeon, Ann-Marie Ablett, volunteer nurse and Orbis ambassador, as well as anesthetist trainee and trainer duo Luu Tong and Andrew Choyce.
Kallikrein Dream
My involvement goes back 35 years. In the 1980s, there was a lot of interest in new biomarkers, and there was a flurry of activity with the discovery of prostate specific antigen (PSA), and a number of other markers, like CA 125 for ovarian cancer, CA 15-3 for breast cancer, and C 19-9, which is used for pancreatic and colon cancer. As a young biochemist, I was fascinated by all these new discoveries, and naturally wanted to get involved.
Eyecare Sans Frontières
Eyecare Sans Frontières How one organization and a flagship aircraft are changing the lives of millions across the globe By Ruth Steer and Roisin McGuigan September 2017 At a Glance Back in 1973, Orbis was founded by a visionary Texan ophthalmologist who wanted to combine eyecare and aviation By 1982, the Flying Eye Hospital was born, and was transporting volunteers worldwide to provide eyecare and outreach programs to those who needed it most Now, the Orbis Flying Eye Hospital is in its...
Undoing the Damage
Fetal alcohol spectrum disorder (FASD) is a widespread problem – up to 11 percent of children are affected.
HED Hair
Researchers link hypohidrotic ectodermal dysplasia and male pattern baldness by studying genetic mutations in humans and mice Roisin McGuigan | 07/19/2017 What do hypohidrotic ectodermal dysplasia (HED) – a condition that results in abnormal development of the skin, hair, nails, teeth and sweat glands – and male pattern baldness (MPB) have in common? According to researchers, the two could be more closely connected than previously thought.
Liquid Assets - The Pathologist
Is ctDNA analysis the future of cancer pathology? We speak with two experts at the leading edge of liquid biopsy Liquid biopsies are becoming increasingly commonplace and, in some cases, are now in clinical use. In cancer, they allow tumor DNA to be sequenced and examined without the need for invasive and potentially risky tissue biopsies. We spoke to two researchers pioneering myriad potential applications of liquid biopsies and circulating tumor DNA (ctDNA).
Hurdles to HIV Survival
A recent study in The Lancet has reported that – thanks to the latest HIV drugs – young adults with the virus can now enjoy a near-normal life expectancy. Today, a 20-year-old who began antiretroviral therapy (ART) in the last few years is estimated to live 10 years longer than a 20-year-old who began ART between 1996 and 1999. But for many patients, barriers to treatment prevent access to this increased life expectancy.
The Six Faces of Streptococcus pneumoniae
Since the first paper describing the phenotypes of pneumococcus was published in 1933, bacteriologists have known that it is able to change forms (and with it, disease severity); but the way in which it does so have remained a mystery. Until now.
The Survival Artists
Mycobacterium tuberculosis is a pathogen known to survive in hostile conditions, but until recently, its ability to survive without oxygen has not been well understood. A recent study from researchers in New Zealand, Germany and the US has managed to shed some light on the subject (1). Up to a third of the world’s population may have a latent TB infection (2), and the researchers hope that discovering mechanisms that allow mycobacteria to survive may lead to new drug targets for TB.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Roisin
Contact Roisin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack